Below are the most recent publications written about "Isocitrate Dehydrogenase" by people in Profiles.
-
Yadav VK, Sharma S, Maurya S, Singh RK, Saini J, Jain P, Patir R, Ahlawat S, Das S, Vaishya S, Agarwal S, Singh A, Gupta RK. Presence of Fragmented Intratumoral Thrombosed Microvasculature in the Necrotic and Peri-Necrotic Regions on SWI Differentiates IDH Wild-Type Glioblastoma From IDH Mutant Grade 4 Astrocytoma. J Magn Reson Imaging. 2025 Jul; 62(1):258-270.
-
Das S, Ahlawat S, Sarangi J, Gupta RK, Jain P, Kate U, Gogi R, Patir R. Oligoastrocytoma: The Vanishing Entity With True Dual Genotype, a Report, its Molecular Profiles and Review of Literature. Int J Surg Pathol. 2025 Aug; 33(5):1216-1223.
-
Alnahhas I. Molecular Testing in Gliomas: What is Necessary in Routine Clinical Practice? Curr Oncol Rep. 2024 Nov; 26(11):1277-1282.
-
Zarei M, Hajihassani O, Hue JJ, Loftus AW, Graor HJ, Nakazzi F, Naji P, Boutros CS, Uppin V, Vaziri-Gohar A, Shalaby AS, Asara JM, Rothermel LD, Brody JR, Winter JM. IDH1 Inhibition Potentiates Chemotherapy Efficacy in Pancreatic Cancer. Cancer Res. 2024 Sep 16; 84(18):3072-3085.
-
Zarnegar-Lumley S, Alonzo TA, Gerbing RB, Othus M, Sun Z, Ries RE, Wang J, Leonti A, Kutny MA, Ostronoff F, Radich JP, Appelbaum FR, Pogosova-Agadjanyan EL, O'Dwyer K, Tallman MS, Litzow M, Atallah E, Cooper TM, Aplenc RA, Abdel-Wahab O, Gamis AS, Luger S, Erba H, Levine R, Kolb EA, Stirewalt DL, Meshinchi S, Tarlock K. Characteristics and prognostic impact of IDH mutations in AML: a?COG, SWOG, and ECOG analysis. Blood Adv. 2023 10 10; 7(19):5941-5953.
-
Setola E, Benini S, Righi A, Gamberi G, Carretta E, Ferrari C, Avnet S, Palmerini E, Magagnoli G, Gambarotti M, Lollini PL, Cesari M, Cocchi S, Paioli A, Longhi A, Scotlandi K, Laginestra MA, Donati DM, Baldini N, Ibrahim T. IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience. BMC Cancer. 2023 Sep 26; 23(1):907.
-
Lee MD, Patel SH, Mohan S, Akbari H, Bakas S, Nasrallah MP, Calabrese E, Rudie J, Villanueva-Meyer J, LaMontagne P, Marcus DS, Colen RR, Balana C, Choi YS, Badve C, Barnholtz-Sloan JS, Sloan AE, Booth TC, Palmer JD, Dicker AP, Flanders AE, Shi W, Griffith B, Poisson LM, Chakravarti A, Mahajan A, Chang S, Orringer D, Davatzikos C, Jain R. Association of partial T2-FLAIR mismatch sign and isocitrate dehydrogenase mutation in WHO grade 4 gliomas: results from the ReSPOND consortium. Neuroradiology. 2023 Sep; 65(9):1343-1352.
-
Miller JJ, Gonzalez Castro LN, McBrayer S, Weller M, Cloughesy T, Portnow J, Andronesi O, Barnholtz-Sloan JS, Baumert BG, Berger MS, Bi WL, Bindra R, Cahill DP, Chang SM, Costello JF, Horbinski C, Huang RY, Jenkins RB, Ligon KL, Mellinghoff IK, Nabors LB, Platten M, Reardon DA, Shi DD, Schiff D, Wick W, Yan H, von Deimling A, van den Bent M, Kaelin WG, Wen PY. Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. Neuro Oncol. 2023 01 05; 25(1):4-25.
-
Vaziri-Gohar A, Cassel J, Mohammed FS, Zarei M, Hue JJ, Hajihassani O, Graor HJ, Srikanth YVV, Karim SA, Abbas A, Prendergast E, Chen V, Katayama ES, Dukleska K, Khokhar I, Andren A, Zhang L, Wu C, Erokwu B, Flask CA, Zarei M, Wang R, Rothermel LD, Romani AMP, Bowers J, Getts R, Tatsuoka C, Morton JP, Bederman I, Brunengraber H, Lyssiotis CA, Salvino JM, Brody JR, Winter JM. Limited nutrient availability in the tumor microenvironment renders pancreatic tumors sensitive to allosteric IDH1 inhibitors. Nat Cancer. 2022 07; 3(7):852-865.
-
Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DVT, Borad MJ, Bridgewater JA, Harris WP, Murphy AG, Oh DY, Whisenant JR, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Chamberlain CX, Aguado-Fraile E, Choe S, Wu B, Liu H, Gliser C, Pandya SS, Valle JW, Abou-Alfa GK. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. JAMA Oncol. 2021 Nov 01; 7(11):1669-1677.